{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:00:54Z","timestamp":1790398854700,"version":"4.1.0"},"reference-count":32,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Merkel Cell Carcinoma (MCC) is a rare, aggressive neuroendocrine and epithelial skin cancer. Somatostatin analogues, such as lanreotide, have shown efficacy in managing other neuroendocrine tumors. Retrospective studies suggest that lanreotide may induce partial response or disease stabilization in patients with advanced MCC. To test this hypothesis, we conducted a Phase II, non\u2010randomized, open trial investigating lanreotide in MCC patients with advanced disease (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                      identifier: NCT02351128).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with Stage IIIB\u2010IV MCC received lanreotide monotherapy (120\u2009mg every 28\u2009days) at any line of systemic therapy, until disease progression or unacceptable toxicity. The primary endpoint was disease control rate (DCR) (defined as the proportion of patients with complete response, partial response, and stable disease) at 3\u2009months. Secondary endpoints included progression\u2010free survival (PFS), overall survival (OS), somatostatin receptor (SSTR) tumor expression, and treatment safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Between April, 2015, and November, 2016, 35 patients received lanreotide, with 12 evaluable at 3\u2009months. The DCR at 3\u2009months was 33.3% (4) among evaluable patients (all with stable disease) and 11.4% for the full cohort. Statistical analyses showed no significant difference from the expected 20% response rate (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.205 for intention\u2010to\u2010treat;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.939 for per\u2010protocol). Kaplan\u2013Meier analysis revealed median OS and PFS of 3.1\u2009months (95% CI, 2\u20135.5) and 3.5\u2009months (95% CI, 2.3\u20135.5), respectively. SSTR tumor expression did not correlate with treatment response.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Although limited by its implementation before the era of immunotherapy, this non\u2010randomized study shows the limited effectiveness of lanreotide as monotherapy in treating patients with advanced MCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>Identifier: NCT02351128<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cam4.72295","type":"journal-article","created":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:42:07Z","timestamp":1790397727000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lanreotide, a Somatostatin Analogue, in Advanced Merkel Cell Carcinoma: A Prospective Single\u2010Arm Phase\n                    <scp>II<\/scp>\n                    Study"],"prefix":"10.1002","volume":"15","author":[{"given":"Julie","family":"Charles","sequence":"first","affiliation":[{"name":"French Network of Rare Skin Cancers CARADERM  France"},{"name":"Dermatology, Allergology and Photobiology Department \u2013 CHU Grenoble Alpes Univ. Grenoble Alpes  Grenoble France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6505-6596","authenticated-orcid":false,"given":"Aude","family":"Belbezier","sequence":"additional","affiliation":[{"name":"Dermatology, Allergology and Photobiology Department \u2013 CHU Grenoble Alpes Univ. Grenoble Alpes  Grenoble France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3880-973X","authenticated-orcid":false,"given":"St\u00e9phane","family":"Mouret","sequence":"additional","affiliation":[{"name":"Dermatology, Allergology and Photobiology Department \u2013 CHU Grenoble Alpes Univ. Grenoble Alpes  Grenoble France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5574-5825","authenticated-orcid":false,"given":"Brigitte","family":"Dreno","sequence":"additional","affiliation":[{"name":"French Network of Rare Skin Cancers CARADERM  France"},{"name":"Dermatology Department CHU de Nantes  Nantes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Dalle","sequence":"additional","affiliation":[{"name":"French Network of Rare Skin Cancers CARADERM  France"},{"name":"Dermatology Department Hospices Civils de Lyon  Pierre\u2010B\u00e9nite France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9leste","family":"Lebbe","sequence":"additional","affiliation":[{"name":"French Network of Rare Skin Cancers CARADERM  France"},{"name":"AP\u2010HP Dermato\u2010Oncology and CIC, Cancer Institute APHP. Nord Paris cit\u00e9, INSERM U1342\u2010Equipe 1\u2010CNRS EMR8000, Saint Louis Hospital Universit\u00e9 Paris Cite  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Hainaut\u2010Wierzbicka","sequence":"additional","affiliation":[{"name":"French Network of Rare Skin Cancers CARADERM  France"},{"name":"Dermatology Department CHU de Poitiers  Poitiers France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreea","family":"Stefan","sequence":"additional","affiliation":[{"name":"French Network of Rare Skin Cancers CARADERM  France"},{"name":"Dermatology Department Centre F. Baclesse  Caen France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"de Quatrebarbes","sequence":"additional","affiliation":[{"name":"French Network of Rare Skin Cancers CARADERM  France"},{"name":"Dermatology Department CH D'annecy  Pringy France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Dereure","sequence":"additional","affiliation":[{"name":"French Network of Rare Skin Cancers CARADERM  France"},{"name":"Dermatology Department CHU de Montpellier, H\u00f4pital Saint Eloi  Montpellier France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9229-1885","authenticated-orcid":false,"given":"Ouidad","family":"Zehou","sequence":"additional","affiliation":[{"name":"French Network of Rare Skin Cancers CARADERM  France"},{"name":"Dermatology Department AP\u2010HP, H\u00f4pital Henri Mondor  Cr\u00e9teil France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Mansard","sequence":"additional","affiliation":[{"name":"French Network of Rare Skin Cancers CARADERM  France"},{"name":"Dermatology Department CHU\u2010Estaing  Clermont\u2010Ferrand France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3212-7455","authenticated-orcid":false,"given":"Alain","family":"Dupuy","sequence":"additional","affiliation":[{"name":"French Network of Rare Skin Cancers CARADERM  France"},{"name":"Dermatology Department CHU de Rennes  Rennes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Dutriaux","sequence":"additional","affiliation":[{"name":"French Network of Rare Skin Cancers CARADERM  France"},{"name":"Dermatology Department CHU de Bordeaux, H\u00f4pital Saint Andr\u00e9  Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florent","family":"Grange","sequence":"additional","affiliation":[{"name":"French Network of Rare Skin Cancers CARADERM  France"},{"name":"Dermatology Department CHU de Reims  Reims France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6955-5117","authenticated-orcid":false,"given":"Caroline","family":"Gaudy\u2010Marqueste","sequence":"additional","affiliation":[{"name":"French Network of Rare Skin Cancers CARADERM  France"},{"name":"APHM, Dermatology and Skin Cancer Department Aix\u2010Marseille Unive  Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0528-4829","authenticated-orcid":false,"given":"Henri","family":"Montaudi\u00e9","sequence":"additional","affiliation":[{"name":"French Network of Rare Skin Cancers CARADERM  France"},{"name":"Dermatology Department CHU de Nice, H\u00f4pital Archet 2  Nice France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6156-473X","authenticated-orcid":false,"given":"Jean\u2010Philippe","family":"Arnault","sequence":"additional","affiliation":[{"name":"French Network of Rare Skin Cancers CARADERM  France"},{"name":"Dermatology Department CH D'amiens Picardie  Amiens France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Le Corre","sequence":"additional","affiliation":[{"name":"French Network of Rare Skin Cancers CARADERM  France"},{"name":"Dermatology Department CHU D'angers  Angers France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2201-6914","authenticated-orcid":false,"given":"Thibault","family":"Kervarrec","sequence":"additional","affiliation":[{"name":"French Network of Rare Skin Cancers CARADERM  France"},{"name":"Pathology Department CHU de Tours  Tours France"},{"name":"Biologie Des Infections \u00e0 Polyomavirus UMR INRA ISP 1282, Universit\u00e9 de Tours  Tours France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3619-7461","authenticated-orcid":false,"given":"Jean\u2010Louis","family":"Quesada","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Unit, INSERM CIC1406 \u2013 CHU Grenoble Alpes Univ. Grenoble Alpes  Grenoble France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahtab","family":"Samimi","sequence":"additional","affiliation":[{"name":"French Network of Rare Skin Cancers CARADERM  France"},{"name":"Pathology Department CHU de Tours  Tours France"},{"name":"Dermatology Department CHU de Tours  Tours France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie\u2010Th\u00e9r\u00e8se","family":"Leccia","sequence":"additional","affiliation":[{"name":"French Network of Rare Skin Cancers CARADERM  France"},{"name":"Dermatology, Allergology and Photobiology Department \u2013 CHU Grenoble Alpes Univ. Grenoble Alpes  Grenoble France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The Group of Cutaneous Oncology of the French Society of Dermatology","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.10.028"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434\u2010016\u20105266\u20104"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1152586"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114261"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01896"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2018.0055"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102387"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.2280"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.03.043"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0002"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102977"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO\u201024\u201002138"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/mc.23042"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.14006"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01529"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13405"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13550\u2010018\u20100423\u20103"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471\u20102407\u201014\u2010268"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19150"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14769"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1159\/000381062"},{"issue":"5","key":"e_1_2_10_23_1","first-page":"161","article-title":"The Expanding Role of Somatostatin Analogs in the Management of Neuroendocrine Tumors","volume":"5","author":"Wolin E. M.","year":"2012","journal-title":"Gastrointest Cancer Res GCR"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.3109\/00016489609137855"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.4103\/0973\u20101482.73352"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434\u2010010\u20100985\u20104"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.721"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2023.2257603"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnmt.122.264904"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1159\/000496335"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01073"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.7150\/thno.91268"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.72295","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.72295","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.72295","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:42:20Z","timestamp":1790397740000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.72295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1002\/cam4.72295"],"URL":"https:\/\/doi.org\/10.1002\/cam4.72295","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"assertion":[{"value":"2026-03-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e72295"}}